1-(1-methyl-1H-imidazol-5-yl)propan-1-one | 592555-22-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-(1-methyl-1H-imidazol-5-yl)propan-1-one
• 英文别名: 1-(3-methylimidazol-4-yl)propan-1-one
• CAS: 592555-22-1
• 化学式: C₇H₁₀N₂O
• mdl: MFCD18811107
• 分子量: 138.169
• InChiKey: QZUSGFQVNBUUPC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.428
• 拓扑面积：
  34.9
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• Imidazole derivatives, production method thereof and use thereof
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP1681290B9

  公开（公告）日：2013-06-19
• FUSED HETEROCYCLIC COMPOUNDS AS SODIUM CHANNEL MODULATORS
  申请人：Gilead Sciences, Inc.

  公开号：EP2707361B1

  公开（公告）日：2017-08-23
• 17-Heterocyclic-4-azasteroid derivatives as androgen receptor modulators
  申请人：Kaufman L. Mildred

  公开号：US20070054933A1

  公开（公告）日：2007-03-08

  Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, benign prostatic hyperplasia (BPH), abdominal adiposity, metabolic syndrome, type II diabetes, cancer cachexia, Alzheimer's disease, muscular dystrophies, cognitive decline, sexual dysfunction, sleep apnea, depression, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.
• LINKED DIBENZIMIDAZOLE DERIVATIVES
  申请人：Or Yat Sun

  公开号：US20100221214A1

  公开（公告）日：2010-09-02

  The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
• LINKED DIIMIDAZOLE DERIVATIVES
  申请人：Qiu Yao-Ling

  公开号：US20100226883A1

  公开（公告）日：2010-09-09

  The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.